Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) (“Cybin” or the “Company”), a clinical-stage neuropsychiatry company focused on advancing mental healthcare through innovative, next-generation treatments, recently shared key clinical accomplishments…
Neuraptive Therapeutics, a biopharmaceutical leader specializing in innovative treatments for peripheral nerve injuries, has announced that interim topline results from their ongoing Phase 2 NEUROFUSE study will be presented at…
Takeda (TOKYO:4502/NYSE: TAK) has announced a commitment of JPY 4.6 billion (approximately USD 32 million) to five new Global Corporate Social Responsibility (CSR) partners. This investment is part of Takeda’s…
Glycomine, Inc., a biotechnology company specializing in treatments for rare diseases, has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to GLM101, a mannose-1-phosphate…
Alzprotect, a French biopharmaceutical company, has successfully completed the open-label extension (OLE) phase following its Phase 2a clinical trial of AZP2006 (ezeprogind®), a treatment for Progressive Supranuclear Palsy (PSP). The…
The report titled “CD137 Antibodies Clinical Trials & Market Opportunity Insight 2027” has been added to ResearchAndMarkets.com’s offerings. CD137, also known as 4-1BB, has emerged as a promising target in…
Wedgewood Pharmacy has officially added molnupiravir to its formulary, offering a new option for the treatment of Feline Infectious Peritonitis (FIP). Originally developed to treat viral infections in humans, including…
Viatris Inc. (NASDAQ: VTRS, “Viatris” or the “Company”) today announced the early results of its subsidiary Utah Acquisition Sub Inc.’s (“UAS”) previously announced cash tender offer (the “Maximum Tender Offer”).…
Blue Cross and Blue Shield of Alabama is dedicated to ensuring its members receive high-quality, affordable care through cost-effective healthcare providers. Starting December 1, 2024, Labcorp, a leader in comprehensive…
Zoetis Inc., the leading global animal health company, is set to launch its new Vetscan OptiCell™ hematology analyzer, a cutting-edge diagnostic tool that combines cartridge-based technology with AI-powered capabilities for…
Novartis announced today that the US Food and Drug Administration (FDA) has approved Kisqali® (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant treatment of patients with hormone…
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has approved OCREVUS ZUNOVO™ (ocrelizumab and hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS)…